January 13 - 17, 2014
Renaissance Hotel and Palm Springs Convention Center Palm Springs, California

A Community Dedicated to the
Evolving Field and Future of Biotherapeutics


Dinner Short Courses* 

Sunday, January 12 | 5:00-8:00 pm 

SC1: Targeting of GPCRs with Monoclonal Antibodies - Detailed Agenda 

While GPCRs (G protein-coupled receptors) are important therapeutic targets, it has been challenging to discover therapeutically relevant antibodies against them.  This course will examine different steps along the anti-GPCR antibody discovery pathway and highlight various approaches to accomplishing each step.  The topics to be covered include: 1) antibody discovery, including methods to generate antibodies and antigen preparation; 2) assays to evaluate antibody binding using cells expressing the GPCR of interest; 3) in vitro assays to measure functional activity of the antibody, including antagonism, agonism, or synergism/allosteric modulation using  chemotaxis, calcium, cAMP or other cell-based assays; and 4) review of promising GPCR targets and therapeutic antibodies currently in  clinical development.


Barbara Swanson, Ph.D., Director, Research, Sorrento Therapeutics, Inc.

SC3: Vaccine Formulation and Characterization, Status Quo and New Opportunities - Detailed Agenda  

After water sanitization, vaccines may be the most successful method to prevent deadly or devastating infectious diseases. To overcome the hurdles that reduce vaccine efficacy, novel techniques to identify and improve vaccines are necessary. These new approaches help increase potency but also challenges related to formulation characterization and the stability of each component. The course will describe the current status of vaccine formulation characterization with a focus on alum-based formulations and describe steps that can improve it.


Michele Pallaoro, Ph.D., Unit Head, Formulation Analytics, Novartis Vaccines & Diagnostics

SC4: QbD Strategies for Formulation Development of Protein Therapeutics - Detailed Agenda 

The course will discuss how to perform protein formulation development to meet QbD expectations from the health authorities. Case studies will be presented on how to conduct Force degradation and stability-indicating analytical methods, design DOE and multivariate experiments and how to analyze data.


Kevin Zen, Ph.D., Manager, Biologics Development, Allergan

Vishal C. Nashine, Ph.D., Senior Research Investigator, Drug Product Science & Technology, Bristol-Myers Squibb Co.

SC5: Advances in Cell Line Engineering - Detailed Agenda 

Discovering and designing novel therapeutic monoclonal antibodies (mAb) is just the beginning. The expanding demand for high-quality antibodies with better specificities has resulted in significant improvements in traditional hybridoma and genetically modified cell line engineering and production methods. However, these newly formed hybridomas and cells often grow poorly or die, and their selection and cloning are laborious and time-consuming. This course is designed to explain recent advances in cell line engineering technologies and provide practical examples through case studies.


Camille Delebecque, Ph.D., Founder and CEO, SynBio Consulting

Robert Horlick, Ph.D., Senior Director, Molecular Biology, AnaptysBio, Inc.

Takeshi Omasa, Ph.D., Professor, Institute of Technology and Science, University of Tokushima

SC6: Strategies for Purifying Proteins: Optimizing Buffers and Overcoming Aggregation - Detailed Agenda 

This course will provide strategies for purifying proteins, such as identifying and overcoming aggregation and stabilizing proteins through buffer optimization, including analyzing quality, pH, salt, stabilizing elements, buffering systems and identifying solubility-promoting buffers.


Sarah Bondos, Ph.D., Assistant Professor, Molecular & Cellular Medicine, Texas A&M University
Mark Arbing, Ph.D., Director, Protein Expression Technology Center, UCLA-DOE Institute for Genomics & Proteomics
Thomas Laue, Ph.D., Professor, Biochemistry and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire


Tuesday, January 14 | 5:00-8:00 pm 

SC9: In silico Immunogenicity Predictions (Hands-On) Workshop - Detailed Agenda  

Computational immunogenicity predictions for antibodies as well as pathogens help in the rational design and re-engineering. This facilitates the minimization of anti-drug antibodies (ADA) as well as better vaccine design. The latest in silico tools can shorten the process from design to preclinical validations.


Vinodh Kurella, Ph.D., Visiting Research Fellow, C3 Bioinformatics, Harvard Medical School

SC10: Protein Aggregation: Mechanism and Characterization - Detailed Agenda 

We will discuss the phenomena described by protein aggregation, how aggregates form, what factors influence their formation and consequences of aggregate formation. We will also discuss how to predict aggregation and key analytical challenges and tools for characterization of aggregates.


Elizabeth M. Topp, Ph.D., Dane O. Kildsig Chair and Head, Industrial and Physical Pharmacy, Purdue University

Daniel Some, Ph.D., Principal Scientist, Wyatt Technology

SC11: Extractables and Leachables: Applications to Final Packaging and Single-Use Systems - Detailed Agenda 

The course will outline fundamentals to material chemistry and leachable sources, while also highlighting properties that govern migration of compounds. Case studies will be presented on how to develop evaluation strategies and design appropriate analytical studies for Controlled Extractables Testing, Leachables Studies and Tox Assessment.


Michael A. Ruberto, Ph.D., President, Material Needs Consulting, LLC

John Iannone, Program Manager and Technical Specialist, Toxikon Corporation

SC12: Transient Protein Production in Mammalian Cells - Detailed Agenda 

We will introduce the fundamental concepts needed to establish transient protein production (TPP) in mammalian cells. TPP allows for the rapid generation of milligram to gram quantities of recombinant proteins for therapeutic, functional and structural studies. This course will provide an introduction to TPP through instruction and case studies in an interactive environment.


Richard Altman, MS, Research Scientist, Alexion Pharmaceuticals

Henry C. Chiou, Ph.D., Senior Product Manager, Life Technologies

Krista Johnson, MSc, Research Scientist, Alexion Pharmaceuticals

SC14: Challenges of Multi-Column Continuous Chromatography - Detailed Agenda  

MCC chromatography in sequential and countercurrent mode has become an attractive tool to overcome the “bottleneck.” Although the SMB technology has a proven record in the manufacture of synthetic pharmaceuticals, barriers still remain to implement the technology into the biopharmaceutical industry.


Dr.-Ing. Kathleen Mihlbachler, Independent Consultant


* Separate registration is required.





Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

PTK Event APP 
New this year!
The PepTalk App will allow attendees to browse the agenda, create custom schedules, navigate the exhibit hall and explore poster presentations.

2014 Brochure Cover 

Right Arrow Download the Brochure 

Right Arrow Event at-a Glance 

      Premier Sponsors: 

EMD Millipore 

 Novozymes (white) 

PerkinElmer NEW 2009 

 Protein Simple  


Right Arrow View All Sponsors 

Right Arrow View Media Partners 

Add to Outlook Add to Outlook 

Training Seminars 

Mon-Tues, January 13-14 

Biologics Formulation and Delivery  


Buzz Sessions
BuzZ Sessions are facilitated, small-group discussions. Interactive participation leads to problem-solving solutions and future collaborations around focused topics.
Click here for BuzZ topics